A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using 18F-Florbetapir

Frontiers in Cardiovascular Medicine

Volumn 2, Issue , 2015, Pages

  Osborne, Dustin R ^a   Acuff, Shelley N ^a   Stuckey, Alan ^a   Wall, Jonathan S ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid; amyloidosis; cardiac; Florbetapir; PET CT

Indexed keywords

EID: 84960129522     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2015.00023     Document Type: Article

References (30)

1. Blancas-Mejía LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem (2013) 82(1):745–74.10.1146/annurev-biochem-072611-13003023451869
2. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 1(2):e000364.10.1161/JAHA.111.000364
3. Ferris HW. Amyloidosis of lungs and heart. Am J Pathol (1936) 12(5):701–18.
4. Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol (2013) 38(2):53–96.10.1016/j.cpcardiol.2012.11.00223337445
5. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart (2012) 98(21):1546–54.10.1136/heartjnl-2012-301924
6. Lie JT. Pathology of amyloidosis and amyloid heart disease. Appl Pathol (1984) 2(6):341–56.6400465
7. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (al) amyloidosis with heart involvement. QJM (1998) 91(2):141–57.10.1093/qjmed/91.2.1419578896
8. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 120(13):1203–12.10.1161/CIRCULATIONAHA.108.84333419752327
9. Picken MM. Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology. Adv Anat Pathol (2013) 20(6):424–39.10.1097/PAP.0b013e3182a92dc324113313
10. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum n-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in al amyloidosis. Circulation (2003) 107(19):2440–5.10.1161/01.CIR.0000068314.02595.B212719281
11. Koyama J, Ray-Sequin PA, Falk RH. Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation (2002) 106(5):556–61.10.1161/01.CIR.0000023530.86718.B012147536
12. Bull S, Loudon M, Ntusi N, Joseph J, Francis J, Ferreira V, et al. Impaired myocardial perfusion in moderate asymptomatic aortic stenosis relates to longitudinal strain but not non-contrast t1 values. J Cardiovasc Magn Reson (2013) 15(Suppl 1):O24.10.1186/1532-429X-15-S1-O24
13. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mtc-dpd scintigraphy in cardiac amyloidosis. J Am Coll Cardiol (2008) 51(15):1509–10.10.1016/j.jacc.2007.12.038
14. Schaadt BK, Hendel HW, Gimsing P, Jonsson V, Pedersen H, Hesse B. 99mtc-aprotinin scintigraphy in amyloidosis. J Nucl Med (2003) 44(2):177–83.
15. Administration, U. F, Drug. Aprotinin Injection (Marketed as Trasylol) Information, Food and Drug Administration in Rockville, MD (2008).
16. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med (2008) 358(22):2319–31.10.1056/NEJMoa080239518480196
17. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol (1985) 6(4):737–43.10.1016/S0735-1097(85)80475-74031287
18. Penugonda N. Cardiac MRI in infiltrative disorders: a concise review. Curr Cardiol Rev (2010) 6(2):134–6.10.2174/15734031079116266821532780
19. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11c-pib and pet. J Nucl Med (2013) 54(2):213–20.10.2967/jnumed.111.10205323238792
20. Okamura N, Yanai K. Florbetapir (18f), a pet imaging agent that binds to amyloid plaques for the potential detection of Alzheimer’s disease. IDrugs (2010) 13(12):890–9.21154149
21. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Jr Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using f-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging (2014) 41(9):1652–62.10.1007/s00259-014-2787-624841414
22. Osborne D, Wells K, Stuckey A, Wilson S, Wall J, Solomon A. Determination of cardiac amyloid involvement using 18f florbetapir and dynamic pet. J Nucl Med (2013) 54(2):2071.
23. Wells K, Osborne D, Stuckey A, Wilson S, Wall J, Solomon A. 18f florbetapir pet/ct cardiac amyloid imaging in patients with systemic amyloidosis. J Nucl Med (2013) 54(2):294.
24. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (al): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, france, 18-22 April 2004. Am J Hematol (2005) 79(4):319–28.10.1002/ajh.2038116044444
25. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82rb dynamic pet imaging. Eur J Nucl Med Mol Imaging (2007) 34(11):1765–74.10.1007/s00259-007-0478-217619189
26. Tahari A, Lee A, Rajaram M, Fukushima K, Lodge MA, Lee BC, et al. Absolute myocardial flow quantification with 82rb pet/ct: comparison of different software packages and methods. Eur J Nucl Med Mol Imaging (2014) 41(1):126–35.10.1007/s00259-013-2537-123982454
27. deKemp RA, Declerck J, Klein R, Pan X-B, Nakazato R, Tonge C, et al. Multisoftware reproducibility study of stress and rest myocardial blood flow assessed with 3d dynamic pet/ct and a 1-tissue-compartment model of 82rb kinetics. J Nucl Med (2013) 54(4):571–7.10.2967/jnumed.112.11221923447656
28. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol (1986) 57(6):450–8.10.1016/0002-9149(86)90771-X2936235
29. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain pet imaging with [18f]av-45, a novel amyloid imaging agent–a pilot study. Nucl Med Biol (2010) 37(4):497–508.10.1016/j.nucmedbio.2010.02.00320447562
30. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18f-av-45: a pet agent for abeta plaques in the brain. J Nucl Med (2009) 50(11):1887–94.10.2967/jnumed.109.06528419837759